贝伐单抗联合化疗治疗卵巢癌的效果及对患者生存质量影响评价
|
摘要
目的在卵巢癌的治疗中应用贝伐单抗、化疗联合治疗方式,分析对患者生存质量的影响。方法以随机的方式选取74例来该院治疗的患者,选取时间为2016年5月—2018年5月。该院按照抽签法将患者分成两组,对照组和实验组,每组37例。对照组在本次调查中采用单纯化疗方式。实验组在该次调查中采用贝伐单抗、化疗联合治疗。观察对照组和实验组治疗效果。结果对照组治疗有效率为24.23%、实验组治疗有效率为72.97%,经对比实验组治疗有效率高于对照组,组间差异有统计学意义(χ~2=17.526 3、P<0.05);治疗后对照组患者生存质量为67.56%低于实验组的94.59%,组间差异有统计学意义(χ~2=6.500 0、P<0.05);实验组不良反应发生率为97.29%高于对照组的94.59%,但组间差异无统计学意义(χ~2=0.555 5、P>0.05)。结论在卵巢癌治疗中可采取贝伐单抗、化疗联合治疗方式,治疗效果显著,值得临床应用和推广。
Objective To analyze the effect of bevacizumab combined with chemotherapy in treatment of oophoroma and effect on the survival quality of patients. Methods 74 cases of patients in our hospital from May 2016 to May 2018 were selected and randomly divided into two groups with 37 cases, the control group used the simple chemotherapy method, while the experimental group used the bevacizumab combined with chemotherapy, and the treatment effect was compared between the two groups. Results The treatment effective rate in the experimental group was higher than that in the control group(24.23% vs 72.97%), and the difference was statistically significant(χ~2=17.526 3, P<0.05), after treatment, the survival quality in the control group was lower than that in the experimental group(67.56% vs 94.59%),and the difference was statistically significant(χ~2=6.500 0, P<0.05), and the incidence rate of adverse reactions in the experimental group was higher than that in the control group(97.29% vs 94.59%), and the difference was not obvious,without statistical significance(χ~2=0.555 5, P>0.05). Conclusion The effect of bevacizumab combined with chemotherapy in treatment of oophoroma is obvious, which is worth clinical application and promotion.
Objective To analyze the effect of bevacizumab combined with chemotherapy in treatment of oophoroma and effect on the survival quality of patients. Methods 74 cases of patients in our hospital from May 2016 to May 2018 were selected and randomly divided into two groups with 37 cases, the control group used the simple chemotherapy method, while the experimental group used the bevacizumab combined with chemotherapy, and the treatment effect was compared between the two groups. Results The treatment effective rate in the experimental group was higher than that in the control group(24.23% vs 72.97%), and the difference was statistically significant(χ~2=17.526 3, P<0.05), after treatment, the survival quality in the control group was lower than that in the experimental group(67.56% vs 94.59%),and the difference was statistically significant(χ~2=6.500 0, P<0.05), and the incidence rate of adverse reactions in the experimental group was higher than that in the control group(97.29% vs 94.59%), and the difference was not obvious,without statistical significance(χ~2=0.555 5, P>0.05). Conclusion The effect of bevacizumab combined with chemotherapy in treatment of oophoroma is obvious, which is worth clinical application and promotion.
引文
[1]马丽芳,周琦,李蓉.贝伐单抗联合化疗对铂敏感型复发性卵巢癌的近期疗效及安全性研究[J].重庆医学,2017,46(11):1532-1535.
[2]韦惠章,潘嘉问,薛协持,等.贝伐珠单抗联合热灌注化疗方案治疗晚期卵巢癌的近远期效果及其对VEGF、HDGF和MIF表达水平的影响[J].中国医药导报,2016,13(8):25-28.
[3]王俊芳,张琴,毛莉,等.腹腔内贝伐珠单抗联合腹腔热灌注化疗治疗卵巢癌腹腔积液的疗效和安全性[J].中国基层医药,2016,23(8):1228-1231.
[4]李丙森,孙夷平,刘虎,等.白蛋白结合型紫杉醇联合贝伐单抗治疗中老年复发转移性卵巢癌的疗效及对患者生存质量的影响[J].中国老年学杂志,2018(10):2358-2360.
[5]毛小刚,江红,刘韵,等.贝伐单抗、紫杉醇、卡帕三者联合治疗复发性卵巢癌的疗效分析[J].实用癌症杂志,2017,32(8):1370-1372.
[6]张丽丽,吕秀萍.腹腔热灌注化疗联合贝伐珠单抗治疗卵巢癌腹腔积液的疗效及生活质量评价[J].中国肿瘤临床与康复,2016(6):753-756.
[7]宓珊,冯华娟,蔡一波,等.贝伐珠单抗联合TP方案治疗晚期卵巢癌患者的护理效果研究[J].实用临床护理学电子杂志,2017,2(9):32-33.
[8]何曾莉,余才锋.贝伐珠单抗联合卡铂治疗晚期卵巢癌的临床疗效及对患者预后生活质量的影响研究[J].山西医药杂志,2018,11(7):35-36.
[9]陈曦,诸一鸣,张平,等.贝伐单抗联合TP方案治疗铂类化疗复发卵巢癌的临床疗效及安全性分析[J].中国生化药物杂志,2017,37(6):366-368.
[10]刘海燕,官燕,孙颖,等.腹腔内贝伐珠单抗联合热化疗对老年卵巢癌患者血转化生长因子β1和巨噬细胞移动抑制因子水平的影响[J].中华老年医学杂志,2018,2(4):55-56.
[2]韦惠章,潘嘉问,薛协持,等.贝伐珠单抗联合热灌注化疗方案治疗晚期卵巢癌的近远期效果及其对VEGF、HDGF和MIF表达水平的影响[J].中国医药导报,2016,13(8):25-28.
[3]王俊芳,张琴,毛莉,等.腹腔内贝伐珠单抗联合腹腔热灌注化疗治疗卵巢癌腹腔积液的疗效和安全性[J].中国基层医药,2016,23(8):1228-1231.
[4]李丙森,孙夷平,刘虎,等.白蛋白结合型紫杉醇联合贝伐单抗治疗中老年复发转移性卵巢癌的疗效及对患者生存质量的影响[J].中国老年学杂志,2018(10):2358-2360.
[5]毛小刚,江红,刘韵,等.贝伐单抗、紫杉醇、卡帕三者联合治疗复发性卵巢癌的疗效分析[J].实用癌症杂志,2017,32(8):1370-1372.
[6]张丽丽,吕秀萍.腹腔热灌注化疗联合贝伐珠单抗治疗卵巢癌腹腔积液的疗效及生活质量评价[J].中国肿瘤临床与康复,2016(6):753-756.
[7]宓珊,冯华娟,蔡一波,等.贝伐珠单抗联合TP方案治疗晚期卵巢癌患者的护理效果研究[J].实用临床护理学电子杂志,2017,2(9):32-33.
[8]何曾莉,余才锋.贝伐珠单抗联合卡铂治疗晚期卵巢癌的临床疗效及对患者预后生活质量的影响研究[J].山西医药杂志,2018,11(7):35-36.
[9]陈曦,诸一鸣,张平,等.贝伐单抗联合TP方案治疗铂类化疗复发卵巢癌的临床疗效及安全性分析[J].中国生化药物杂志,2017,37(6):366-368.
[10]刘海燕,官燕,孙颖,等.腹腔内贝伐珠单抗联合热化疗对老年卵巢癌患者血转化生长因子β1和巨噬细胞移动抑制因子水平的影响[J].中华老年医学杂志,2018,2(4):55-56.